Meng Qiu

机构：Sichuan University, Sichuan Cancer Hospital, Henan University of Economic and Law · ORCID：0000-0003-3722-6938

发表论文 202 篇 · 总被引 3731 次 · h-index 32

代表论文

• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial (2025 · The Lancet · 被引 128)
• Advances in nitrogen-containing helicenes: synthesis, chiroptical properties, and optoelectronic applications (2025 · Beilstein Journal of Organic Chemistry · 被引 17)
• Molecular insights into TT2-type MYB regulators illuminate the complexity of floral flavonoids biosynthesis in Freesia hybrida (2024 · Horticulture Research · 被引 14)
• The multi-target mechanism of action of Selaginella doederleinii Hieron in the treatment of nasopharyngeal carcinoma: a network pharmacology and multi-omics analysis (2025 · Scientific Reports · 被引 9)
• Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial) (2025 · BMJ Open · 被引 5)
• Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01). (2025 · Journal of Clinical Oncology · 被引 3)